Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Wantai Biological Pharmacy Enterprise Co's revenue for the
three
months ended in Jun. 2026 was ¥525 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ¥2,024 Mil.
Beijing Wantai Biological Pharmacy Enterprise Co's Revenue per Share for the
three
months ended in Jun. 2026 was ¥0.42.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1.60.
Warning Sign:
Beijing Wantai Biological Pharmacy Enterprise Co Ltd revenue per share has been in decline for the last 5 years.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Beijing Wantai Biological Pharmacy Enterprise Co Revenue Related Terms
Beijing Wantai Biological Pharmacy Enterprise Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co Revenue Chart
Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Wantai Biological Pharmacy Enterprise Co Revenue vs Biotechnology Industry
Beijing Wantai Biological Pharmacy Enterprise Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,024 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a Revenue of ¥2,024 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors.
Is Beijing Wantai Biological Pharmacy Enterprise Co's Revenue too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current Revenue is ¥2,024 Mil. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's Revenue compare to VRTX and REGN?
Beijing Wantai Biological Pharmacy Enterprise Co's Revenue of ¥2,024 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. Beijing Wantai Biological Pharmacy Enterprise Co's current Revenue is ¥2,024 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥48.02, compared to a current price of ¥26.01 — trading 45.8% below its estimated fair value. The current Revenue is ¥2,024 Mil. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current Revenue is ¥2,024 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued.
The current stock price of ¥26.01 is trading 45.8% below its estimated GF Value™ of ¥48.02.
GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.
Key valuation signals for SHSE:603392:
Revenue: ¥2,024 Mil
GF Value™: ¥48.02 vs. price of ¥26.01 (45.8% below fair value)
No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
49GF Score
Get the complete analysis for SHSE:603392
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603392 has been successfully added to your 
